Crown Bioscience Expands Capabilities

Crown Bioscience has entered an exclusive preclinical services alliance for the largest collection of naturally occurring diabetic translational models. The models are designed for research involving cardiovascular and metabolic diseases, including spontaneous developed diabetes and its complications. They were developed to mirror aspects of human disease related to obesity, nephropathy, hyperglycemia, hyperinsulinemia, dyslipidemia, glucose intolerance, reduced glucose disposition, insulin resistance and late stage insulin dependency.

“Our translational models give sponsors a high level of confidence when deciding to move a drug candidate into clinical development by providing insights into the pharmacological mechanisms of a drug and identifying biomarkers important to clinical trial design,” said Jean-Pierre Wery, Ph.D., president of Crown Bioscience.
 
Also, Zhen Pang, M.D., an expert in transgenic models, has been named scientific director. Previously, Dr. Pang held key positions as principal research investigator at several global biopharmaceutical companies, working in metabolic diseases as well as a variety of therapeutic areas.
 
“We are experiencing substantial growth in demand for our cardiovascular and metabolic disease (CVMD) services because of our depth and capability in cardiovascular and diabetic research,” said Jim Wang, M.D., senior vice president of CVMD research at Crown Bioscience. “With the expansion of our CVMD program in the U.S. and China, as well as the appointment of Dr. Pang, we are able to provide cutting-edge translational platforms and cost-effective drug development solutions to top pharmaceutical companies worldwide.”